中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
20期
133-134
,共2页
依达拉奉%血栓通%急性脑梗死
依達拉奉%血栓通%急性腦梗死
의체랍봉%혈전통%급성뇌경사
Edaravone%Xueshuantong%Acute cerebral infarction
目的：分析依达拉奉联合血栓通治疗急性脑梗死的临床疗效。方法将95例患者分为两组，治疗组52例在对照组43例血栓通治疗基础上联合依达拉奉。结果治疗组总有效率96.2%，高于对照组的79.1%，血清CRP低于对照组，血液流变学较对照组改善，P<0.05，无不良反应。结论依达拉奉联合血栓通治疗急性脑梗死取得让人满意的效果。
目的：分析依達拉奉聯閤血栓通治療急性腦梗死的臨床療效。方法將95例患者分為兩組，治療組52例在對照組43例血栓通治療基礎上聯閤依達拉奉。結果治療組總有效率96.2%，高于對照組的79.1%，血清CRP低于對照組，血液流變學較對照組改善，P<0.05，無不良反應。結論依達拉奉聯閤血栓通治療急性腦梗死取得讓人滿意的效果。
목적：분석의체랍봉연합혈전통치료급성뇌경사적림상료효。방법장95례환자분위량조，치료조52례재대조조43례혈전통치료기출상연합의체랍봉。결과치료조총유효솔96.2%，고우대조조적79.1%，혈청CRP저우대조조，혈액류변학교대조조개선，P<0.05，무불량반응。결론의체랍봉연합혈전통치료급성뇌경사취득양인만의적효과。
ObjectiveTo analyze the clinical efficacy of edaravone and xueshuantong treatment in acute cerebral infarction.Methods Ninety-five patients were divided into two groups,52 patients in study group were xueshuantong treatment plus edaravone and 43 patients in control group were given xueshuantong treatment. Results The total efficiency in study group(96.2%)was higher than control group (79.1%),serum CRP was lower than the control group,improve blood rheology was better than the control group,P< 0.05,no adverse reactions.Conclusion Edaravone treatment of acute cerebral infarction xueshuantong achieved satisfactory results.
